Original assessment ยท live

MSFT: Buy

Published 16 Sep 2026, 06:58 BST. This is the frozen version, not the current recommendation.

Target$728.09
Target date2027-09-11
Price known at publication$495.632026-09-11

Why this assessment was issued

The model version changed. The published model version has been replaced. Record the new calculation basis even if the rating is unchanged. Profitable growth supports the valuation. The price clears the return, cash, borrowing and downside requirements.

Profitable growth supports the valuation. The price clears the return, cash, borrowing and downside requirements.

Supporting evidence

Quarterly sales are growing

Revenue changed +17.7% from the same quarter last year, through 2026-06-30. The previous quarterโ€™s year-on-year change was +18.3%.

The stock is leading its sector

Over one year, the stock changed -2.8% against -30.7% for Technology (XLK). The gap is +27.9 percentage points. These are price returns, before dividends.

Opposing evidence

Capital spending changes the cash picture

Operating cash covers 1.37 times profit, but cash after capital spending covers 0.50 times. Cash generation is stronger before the investment bill is paid.

Working capital is growing faster than sales

Inventory changed +48.9%, against sales of +17.7%, from the same quarter last year. This can tie up cash. Acquisitions, payment timing and seasonality also need checking.

The original scenarios

ScenarioSales growthProfit marginModel value
Weaker13.0%34.4%$559.92
Central18.0%38.2%$728.09
Stronger23.0%42.0%$925.93

Method: Earnings and historical valuation. A sufficiently complete, positive earnings record allows the stock's own P/E history to be used. These scenarios are not probability intervals.

Original assumptions and checks
eps17.89
cash20935000000.0
debt128808300000.0
years1.1991786447638604
growth18.022027401417894
margin40.30538905915218
profit133749000000.0
cash_okTrue
debt_okTrue
growths[18.431043683769154, 16.717888327205888, 18.2970342248737, 17.74702057796209]
revenue331839000000.0
downside0
leverage0.5429363062133528
multiple35.17922077922078
free_cash66987000000.0
buy_hurdle23.53932422016404
volatility37.07864844032808
history_end2026-09-11
reward_riskNot available
annual_years5
usable_weeks157
history_start2023-09-15
history_weeks157
financial_date2026-06-30
interest_cover50.880694854146185
operating_cash182935000000.0
uncapped_growth18.022027401417894
current_multiple27.704304080491895
projected_margin38.22570215405963
historical_margin36.146015248967075

Recent price ยท Passed. Weekly close dated 2026-09-11.

Suitable business model ยท Passed. Value operating cash flow or comparable earnings; deduct debt and other ownership claims where appropriate.

Four quarters ยท Passed. Four quarters ending 2026-06-30.

Current financials ยท Passed. Statements through 2026-06-30; factor prices dated 2026-09-11.

Annual record ยท Passed. 5 consecutive annual profit margins, including loss years.

Comparable earnings history ยท Passed. P/E is usable in 157 of 157 weeks. At least 52 usable weeks and 70% coverage are required; excluding too many loss or missing weeks would bias the target.

Earnings and price dates ยท Passed. Earnings-release EPS $17.89, for four quarters ending 2026-06-30.

Price risk ยท Passed. Risk uses the latest 52 weekly price changes.

Comparable sales growth ยท Passed. Growth uses the median of four quarterly year-on-year comparisons.

Positive statement earnings ยท Passed. Trailing statement profit is positive.

Earnings reconciliation ยท Passed. Release EPS is $17.89; statement-derived EPS is $18.01. The difference is within the 5% review threshold; this does not prove there are no unusual items.

Statement totals ยท Passed. The latest four quarters agree with the trailing snapshot within 5%.

Cash and borrowing ยท Passed. Cash generation, debt and interest-cover figures are available.

Target publication review ยท Passed. The model estimate is within SM's automatic publication range of one quarter to four times the current price. This is a review threshold, not evidence that the market price is correct.

Policy sm-review-2-research ยท Model sm-assessment-13-assumption-review ยท Data 80e98f9f8785.

Open current research โ†—

Evidence context